Rubius Therapeutics Inc (NASDAQ:RUBY) shares saw strong trading volume on Friday . 2,834,366 shares were traded during mid-day trading, an increase of 825% from the previous session’s volume of 306,401 shares.The stock last traded at $16.29 and had previously closed at $15.58.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Rubius Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. ValuEngine lowered shares of Rubius Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. Finally, Morgan Stanley lowered their price objective on shares of Rubius Therapeutics from $37.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, December 19th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $30.00.
The company has a debt-to-equity ratio of 0.06, a current ratio of 25.78 and a quick ratio of 25.78.
TRADEMARK VIOLATION NOTICE: “Rubius Therapeutics (RUBY) Sees Strong Trading Volume” was reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.wkrb13.com/2019/03/16/rubius-therapeutics-ruby-sees-strong-trading-volume.html.
About Rubius Therapeutics (NASDAQ:RUBY)
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
See Also: What is a Reverse Stock Split?
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.